Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
PDF | HTML | How to cite
Metrics: PDF 1494 views | HTML 2069 views | ?
Takuya Watanabe1, Katsuhiro Okuda1, Takayuki Murase2, Satoru Moriyama1, Hiroshi Haneda1, Osamu Kawano1, Keisuke Yokota1, Tadashi Sakane1, Risa Oda1, Hiroshi Inagaki2 and Ryoichi Nakanishi1
1Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan
2Department of Pathology and Molecular Diagnostics, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan
Katsuhiro Okuda, email: [email protected]
Keywords: malignant pleural mesothelioma (MPM); programmed death 1 (PD-1); programmed death ligand 1 (PD-L1); immunohistochemistry (IHC); immune checkpoint inhibitors (ICIs)
Received: January 29, 2018 Accepted: March 24, 2018 Published: April 17, 2018
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 pathway are expected to be a novel therapy for combating future increases in numbers of malignant pleural mesothelioma (MPM) patients. However, the PD-L1 expression, which is a predictor of the response to ICIs, is unclear in MPM. We studied the PD-L1 expression using four immunohistochemical assays (SP142, SP263, 28-8 and 22C3) in 32 MPM patients. The PD-L1 expression in tumor cells and immune cells was evaluated to clarify the rate of PD-L1 expression and the concordance among the four assays in MPM. The positivity rate of PD-L1 expression was 53.1% for SP142, 28.1% for SP263, 53.1% for 28-8, and 56.3% for 22C3. Nine cases were positive and 10 were negative for all assays. Discordance among the four assays was found in 13 cases. The concordance rates between SP142 and 22C3 and between 28-8 and 22C3 were the highest (84.4%). The concordance rates between SP263 and the other three assays were low (71.9% to 75.0%). The PD-L1 expression in MPM was almost equivalent for three of the assays. Given the cut-off values set in our study, these findings suggested that these assays, except for SP263, can be used for accurate PD-L1 immunostaining in MPM.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.